Evidence map›Paper›PMID 40810104›Full record

ArticleJHEP reports : innovation in hepatology2025

Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.

Maryam Motamedrad, Maryam Ebadi, Norberto Sanchez-Fernandez, Alessandro Parente, Abha R Dunichand-Hoedl, Elora Rider, Norman M Kneteman, A M James Shapiro, David Bigam, Khaled Dajani and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Conjugated Bile Acids Profile Suggests a Novel Liver-Muscle Axis Associated With Sarcopenia in Chronic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maryam MotamedradDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.
Maryam EbadiDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.
Norberto Sanchez-FernandezDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
Alessandro ParenteDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
Abha R Dunichand-HoedlDivision of Human Nutrition, University of Alberta, Edmonton, Alberta, Canada.
Elora RiderDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.
Norman M KnetemanDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
A M James ShapiroDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
David BigamDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
Khaled DajaniDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
Blaire AndersonDivision of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada.
Vickie E BaracosDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Vera MazurakDivision of Human Nutrition, University of Alberta, Edmonton, Alberta, Canada.
Aldo J Montano-LozaDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Loss of skeletal muscle mass is a common complication in cirrhosis that is associated with higher morbidity and mortality. Since the specific pathophysiology of cirrhosis-related muscle loss is unclear, we performed histological evaluation of muscle tissue from patients with cirrhosis undergoing liver transplantation (LT). Methods: Results: At LT, 39 patients (68.4%) had decompensated cirrhosis. Decompensated cirrhosis was associated with reduced skeletal muscle index (females: 37.5 ± 4.5 Conclusions: Patients with decompensated cirrhosis have myopathy characterized by fibre type II atrophy and disruption of nuclear positioning. Further work is warranted to evaluate the factors related to the development of muscle pathology in cirrhosis and to develop regimens of muscle rehabilitation for this patient population pre- and post-LT. Impact and implications: Our study illustrates the presence of myopathy at the histological level in patients with cirrhosis undergoing liver transplantation. Patients with decompensated cirrhosis, compared with compensated cirrhosis, exhibit type II (glycolytic) muscle fibre atrophy and disruption of nuclear positioning. Patients with decompensated cirrhosis gain an extended survival benefit from liver transplantation but are likely to begin this extension of life enfeebled by loss of muscle mass and function. The involvement of glycolytic muscle fibres may have implications for strength and fatiguability; thus, post-transplant resistance exercise may help with rehabilitation.

Indexed as

cirrhosisdecompensationliver transplantationmuscle mass

Identifiers

PMID40810104
PMCPMC12341602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.